This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Hall, G. L. Articles by Risk, J. M. Search for Related Content PubMed PubMed Citation Articles by Hall, G. L. Articles by Risk, J. M. Related Collections Risk Assessment Risk Assessment: Biomarkers

p16 Promoter Methylation Is a Potential Predictor of Malignant Transformation in Oral Epithelial Dysplasia

¹ Molecular Genetics and Oncology Group, ² Department of Oral Pathology, School of Dental Sciences, University of Liverpool, ³ Division of Surgery and Oncology, School of Cancer Studies, University of Liverpool, Royal Liverpool University Hospital, ⁴ Regional Maxillofacial Unit, University Hospital Aintree, and ⁵ University of Liverpool Cancer Research Centre, Roy Castle Lung Cancer Research Programme, Liverpool, United Kingdom

Requests for reprints: Janet M. Risk, Molecular Genetics and Oncology Group, Department of Clinical Dental Sciences, University of Liverpool, Liverpool L69 3GN, United Kingdom. Phone: 441-517-065265; Fax: 441-517-065809. E-mail: j.m.risk{at}liverpool.ac.uk

Management of the patient with oral epithelial dysplasia depends on the ability to predict malignant transformation. Histologic grading of this condition fails in this regard and is also subject to interpathologist and intrapathologist variability. This study uses longitudinal clinical samples to explore the prognostic value of a previously validated panel of methylation biomarkers in a cohort of patients with histologically proven oral dysplasia. Methylation enrichment pyrosequencing assays were used to provide the sensitivity of traditional methylation-specific PCR with the additional specificity advantages of a subsequent confirmatory sequencing reaction. In 57% (8 of 14) patients with a lesion that transformed to oral squamous cell carcinoma, 26% (26 of 100) of longitudinal samples collected over 3 years showed p16 methylation. Only 1% (2 of 184) of samples from 8% of patients (2 of 24) not undergoing malignant transformation within 3 years had p16 methylation. Both of these samples with p16 promoter methylation were the most recently collected and the patients remain under continuing clinical review. Promoter methylation of MGMT, CYGB, and CCNA1 did not correlate with malignant progression. We thus conclude that methylation of the p16 gene promoter shows promise as a predictor for malignant transformation (Fisher's exact, P = 0.002) in a subset of patients. (Cancer Epidemiol Biomarkers Prev 2008;17(8):2174–9)

This article has been cited by other articles:

				S.P. Barros and S. Offenbacher Epigenetics: Connecting Environment and Genotype to Phenotype and Disease Journal of Dental Research, May 1, 2009; 88(5): 400 - 408. [Abstract] [Full Text] [PDF]